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Introduction: Isolated local recurrence of prostate cancer following primary radiotherapy or brachyther-
apy may be treated with focal salvage high dose rate brachytherapy, although there remains an absence
of high quality evidence to support this approach.
Methods: Men with prostate cancer treated consecutively between 2015 and 2018 using 19 Gy in a single
fraction high dose rate brachytherapy (HDR) for locally recurrent prostate cancer were identified from an
institutional database. Univariable analysis was performed to evaluate the relationship between patient,
disease and treatment factors with biochemical progression free survival (bPFS).
Results: 43 patients were eligible for evaluation. Median follow up duration was 26 months (range 1–60).
Median bPFS was 35 months (95% confidence interval 25.6–44.4). Kaplan-Meier estimates for bPFS at 1, 2
and 3 years post salvage were 95.2%, 70.6% and 41.8% respectively. On univariable Cox regression anal-
ysis, only nadir PSA was significantly associated with bPFS although the majority of patients were also
treated with androgen deprivation therapy. Only one late grade 3 genitourinary toxicity was observed.
Conclusion: Focal salvage HDR brachytherapy may provide good biochemical control with a low risk of
severe toxicity. Further evaluation within clinical trials are needed to establish its role in the manage-
ment of locally recurrent prostate cancer.
 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Several modalities are available for the treatment of localised
prostate cancer (PCa) including radical prostatectomy (RP), exter-
nal beam radiotherapy (EBRT), brachytherapy and combination
brachytherapy/EBRT. Despite technical advancements in the deliv-
ery of dose-escalated radiation to the prostate, locally persistent/
recurrent disease may occur following primary treatment [1–4].Most patients with recurrent PCa are treated with palliative
androgen deprivation therapy (ADT) [5]. However, for patients
with confirmed isolated local disease, salvage therapies including
low dose rate (LDR) and high dose rate (HDR) brachytherapy,
high-intensity focussed ultrasound (HIFU), cryoablation and RP
represent a radical alternative with the aim of local disease control
and preventing development of metastases [6,7].
Given the concerns regarding the toxicity of whole-gland sal-
vage therapies, it has been suggested that focal salvage therapy
using brachytherapy could be an effective but better tolerated
alternative and some prospective early phase studies of focal sal-
vage HDR brachytherapy have been reported [8–10]. Advance-
ments in multiparametric magnetic resonance imaging (mp-MRI),
positron emission tomography combined with computed tomogra-
phy (PET-CT) and template-guided biopsies help to localise of the
specific area of disease within the prostate to permit precise
delivery of focal treatments [11,12]. At this stage however, there
remains limited clinical data and an absence of high quality
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[8–10,13–15].
We therefore present our efficacy and toxicity outcomes for
patients treated at our institution with focal salvage HDR
brachytherapy for locally recurrent PCa.2. Methods
2.1. Patient population
Between 2015 and 2018, 43 patients consecutively treated for
locally recurrent PCa using focal salvage HDR brachytherapy at a
single centre were retrospectively identified from an institutional
database. Primary disease was classified using National Compre-
hensive Cancer Network (NCCN) criteria version 4.2019. Interme-
diate risk disease was defined as the presence of one or more of
the following factors: T2b-2c disease, prostate specific antigen
(PSA)  10–20 ng/ml or Gleason score 7 (ISUP Grade 2 or 3). High
risk disease was defined as the presence of one or more of the fol-
lowing factors: T3a disease, PSA  20 ng/ml or Gleason score  8
(ISUP Grade 4 or 5). Radiological staging used the AJCC TNM 7 sys-
tem. Relapse following primary treatment was identified by serial
measurement of PSA. Radiological confirmation of locally recurrent
disease was determined using a combination of mp-MRI pelvis
(which includedT2-weighted (T2W), dynamic contrast-enhanced
(DWE) and diffusion weighted (DWI) sequences) and whole body
PET-CT (fludeoxyglucose 18 (18F) choline or 18F-fluorocyclobu
tane-1-carboxylic acid fluciclovine (FACBC, fluciclovine) PET-CT).
Histological confirmation of locally recurrent PCa was identified
using transperineal biopsy.
2.2. Treatment
2.2.1. Primary treatment
All patients received primary treatment using EBRT or LDR
brachytherapy. Primary treatment with RP, prostate volume
greater than 50 cc, IPSS score greater than 15 andmedical unfitness
for general anaesthesia were exclusion criteria.
2.2.2. HDR brachytherapy technique:
Focal salvage HDR brachytherapy was performed using tran-
srectal ultrasound (TRUS) guidance under general anaesthesia.
The gross tumour volume (GTV) was identified based on cognitive
fusion of mp-MRI, PET-CT images, template-guided biopsy results
and TRUS images. Metal catheters were inserted via transperineal
approach to ensure adequate coverage of the GTV. The GTV, ure-
thra and rectum were outlined on TRUS images by a consultant
radiologist. The PTV was generated by an isotropic expansion of
3 mm in all directions but constrained by the rectum posteriorly.
Treatment plans were generated using dose-volume histogram
(DVH)-based inverse optimisation in Oncentra ProstateTM v4.2, with
minor manual adjustments to dwell times applied if necessary to
meet the plan objectives and constraints. The PTV dose objectives
were 19 Gy in a single fraction to 100% isodose and D90 focal
PTV > 17.1 Gy (90%). The organ at risk (OAR) constraints for the rec-
tum were V100% =0, and D2cc < 12.35 Gy (65%) and for the urethra
a hard constraint of D10% <20.9 Gy (110%).
2.2.3. Androgen deprivation therapy (ADT)
The majority of patients received ADT, either by 3 monthly
LHRH agonist subcutaneous injection (Prostap 11.25 mg or Zoladex
10.8 mg) or bicalutamide 150 mg once daily tablet. Duration of
ADT varied between 6 and 36 months in patients with hormone
naïve PCa and continued to be administered in patients with
castrate-resistant PCa. Where it was commenced for this relapse,ADT was started as neoadjuvant therapy 3 months prior to the
BT implant and the remaining course was given as adjuvant
therapy.
2.2.4. Follow up
As per our departmental protocol, patients were followed up
using PSA at 6 monthly intervals for the first 3 years post treatment
and annually thereafter. Relapse following focal salvage HDR
brachytherapy was classified as either biochemical or radiological
(whichever occurred earlier). Biochemical relapse was defined as
a PSA of plus 2 ng/ml above the nadir value post salvage treatment.
Radiological relapse was defined as radiological evidence of disease
progression. Acute and late genitourinary (GU) and gastrointestinal
(GI) toxicities were evaluated. Acute toxicity was defined as occur-
ring less than 3 months following salvage treatment.
2.3. Study endpoints
The primary endpoint of this study was to evaluate biochemical
progression free survival (bPFS) following focal salvage HDR
brachytherapy. The secondary endpoint was to report the inci-
dence of GU and GI toxicities, evaluated using Common Terminol-
ogy Criteria for Adverse Events version 4.0 (CTCAE, National Cancer
Institute).
2.4. Statistical analysis
Descriptive statistics were performed to evaluate patient, dis-
ease and treatment characteristics for both primary and recurrent
disease. Statistical analysis was performed using IBM SPSS ver-
sion 21 (IBM, USA). Duration of follow up was calculated from
the date of the HDR brachytherapy procedure. Actuarial bPFS sur-
vival curves were generated using the Kaplan-Meier method. Uni-
variable Cox regression analyses were performed for the following
variables to test for association with bPFS: primary disease risk cat-
egory; primary tumour T stage; presenting PSA; primary tumour
ISUP score (evaluated as individual scores and as groups 1–2, 3
and 4–5); primary prostate treatment; time to relapse after pri-
mary treatment; recurrent tumour ISUP score; ADT administered
with salvage HDR brachytherapy or not; nadir PSA post salvage
and D90 focal PTV value. A p value of <0.05 was taken to indicate
a statistically significant association between the evaluated factor
and bPFS.
3. Results
3.1. Primary treatment
A summary of baseline patient, disease and treatment charac-
teristics is shown in Table 1. Median time between completion of
primary treatment and first relapse (defined as either PSA plus
2 ng/ml above the nadir value post primary treatment or histolog-
ical evidence of locally recurrent disease where PSA had not
reached plus 2 ng/ml above the nadir value) was 70 months (95%
confidence interval (CI) 60–80). First identifiable failure of primary
treatment was biochemical in 39 patients (91%) and histological in
4 patients (9%).
3.2. Focal salvage HDR brachytherapy
43 patients were evaluable. A summary of disease and treat-
ment characteristics prior to focal salvage HDR brachytherapy is
shown in Table 2. Staging investigations prior to salvage treatment
included both MRI pelvis and PET-CT, MRI pelvis alone and PET-CT
alone in 26, 9 and 8 patients respectively. All patients had histolog-
Table 1
Baseline patient, disease and treatment characteristics.
Characteristic Number (%)
Number of patients 43
Median age (range) 70 (62–81)
Median presenting PSA (range) 10.5 (3.4–178)
Primary tumour T stage
T1 13 (31%)
T2 18 (42%)
T3a 4 (9%)
T3b 7 (16%)
T4 1 (2%)
Primary tumour ISUP grade
1 21 (49%)
2 14 (33%)
3 4 (9%)
4 2 (5%)
5 2 (5%)
Primary tumour risk category
Low 13 (30%)
Intermediate 17 (40%)
High 13 (30%)
Primary prostate cancer treatment
EBRT 15 (35%)
LDR brachytherapy 28 (65%)
Hormone therapy with primary treatment
None 26 (60%)
6 months 5 (12%)
2–3 years 10 (23%)
>3 years 1 (2%)
Unknown 1 (2%)
Table 2
Characteristics of disease relapse prior to focal salvage HDR brachytherapy.
Characteristic Number (%)
Type of failure of primary treatment
Biochemical 39 (91%)
Histological 4 (9%)
Median PSA at relapse (range) 3.1 (1.1–7.5)
Type of biopsy
Full template 3 (7%)
Four quadrants 24 (56%)
Four quadrants + targeted 13 (30%)
Targeted only 2 (5%)
TRUS 1 (2%)
Re-biopsy ISUP grade
1 2 (5%)
2 13 (30%)
3 11 (26%)
4 6 (14%)
5 7 (16%)
Ungradable 4 (9%)
ISUP upgraded at re-biopsy
Yes 27 (63%)
No 12 (28%)
Ungradable 4 (9%)
Imaging prior to salvage HDR brachytherapy
MRI alone 9 (21%)
PET-CT alone 8 (19%)
Both MRI and PET-CT 26 (60%)
Dose/fractionation of focal salvage HDR
brachytherapy
19 Gy in one fraction
(100%)
ADT with focal salvage HDR brachytherapy
None 11 (26%)
6 months 19 (44%)
2–3 years 9 (21%)
Castrate resistant- continued hormone therapy 4 (9%)
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was done by trans-perineal biopsies from four quadrants (left and
right superior and inferior) ± targeted biopsies. 3 patients (7%)
underwent full template-guided biopsies. Fig. 1 illustrates the site
of relapse for all 43 patients as evaluated by biopsy.All patients were treated using 19 Gy in a single fraction. ADT
was administered in 74% of cases- for 6 months in 44% and
between 2 and 3 years in 21% of cases. 4 patients (9%) were
castrate-resistant at time of salvage treatment and continued on
ADT.
Median duration of follow up was 26 months (interquartile
range 21.5–41.5, range 1–60). Median bPFS following focal salvage
HDR brachytherapy was 35 months (95% CI 25.6–44.4) and is illus-
trated in Fig. 2. Kaplan-Meier estimates for bPFS at 1, 2 and 3 years
post salvage were 95.2%, 70.6% and 41.8% respectively. Of the
patient, disease and treatment-related factor evaluated using uni-
variable Cox regression analysis, only nadir PSA was significantly
associated with bPFS. Median nadir PSA post salvage was
0.24 ng/ml (range 0.01–2.8). But in patients with nadir PSA < 0.2
ng/ml, the median bPFS was 47 months compared with 28 months
for those with nadir PSA > 0.2 ng/ml (HR 4.47, 95% CI 1.4–14.2,
p = 0.06). No other factor evaluated by univariable analysis was sig-
nificantly associated with bPFS. There appeared to be a non-
significant trend to improved bPFS post salvage for patients with
time to relapse after primary treatment longer than 30 months.
Median bPFS was for those with a relapse free
period > 30 months and < 30 months was 36 versus 21 months
respectively (p = 0.288).
17 patients experienced further disease progression following
salvage HDR. Of these, the first treatment failure was biochemical
progression in 14 patients and radiological evidence of progression
in 3 patients. Median PSA at time of further relapse was 2.7 ng/ml
(range 1.5–9.8). At the time of last follow up, the majority of
patients who relapsed had either received no further treatment
or were treated with ADT with palliative intent. Of patients who
had undergone restaging imaging after disease progression was
first detected, six patients had local recurrence alone, one had both
local and regional nodal recurrence and one patient had developed
distant metastatic disease. No patient had died. Table 3 sum-
marises outcomes and further treatments following focal salvage
HDR brachytherapy.
3.3. HDR dosimetry
The planning dose objectives and achieved dosimetry are indi-
cated in Table 4. The focal PTV D90 aim was adhered to by 95%
of plans. Achievable coverage was dependent on the location of
the Focal-PTV with respect to the organs at risk and in particular
the urethra. All plans fulfilled the dose constraint for the rectum
and the hard dose constraint for the urethra.
3.4. Toxicity
Incidences of acute and late GU and GI toxicities are shown in
Table 5. grade 2 acute GU and GI toxicities occurred in 39 (91%)
and 6 (14%) patients respectively. grade 2 late GU and GI toxici-
ties occurred in 28 (65%) and 6 (14%) patients respectively. Only
one (2%) grade 3 late GU toxicity was observed in a patient who
underwent urethrotomy for a urethral stricture at 36 months.4. Discussion
This single-centre, retrospective study represents one of the lar-
gest reported series of patients treated using focal salvage HDR
brachytherapy for locally recurrent PCa. We evaluated bPFS and
toxicity outcomes and these suggest that it is feasible to obtain
good biochemical control with relatively low morbidity using this
technique. Despite interest in whole gland and focal salvage HDR
and LDR brachytherapy, there remains an absence of high quality
evidence to guide their use in locally relapsed PCa. The European
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Fig. 1. Distribution of sites of relapse in 43 patients as evaluated by biopsy prior to focal salvage HDR brachytherapy. Note that the total number of relapses exceeds 43 since
multiple sites were positive in some patients. L, left; R, right; ant, anterior gland; mid, mid gland; post, posterior gland; SV, seminal vesicle; NOS, not otherwise specified.
Fig. 2. Kaplan-Meier survival plot showing biochemical progression free survival for the entire cohort (n = 43 patients).
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brachytherapy is not offered as a treatment for proven local recur-
rence because it is still experimental and requires further evalua-
tion within clinical trials [6]. In a recent Delphi consensus study
of salvage brachytherapy, agreement was reached for only 22% of
questions concerning treatment technique, dosimetry and use ofADT and for approximately 50% of questions regarding patient
selection and pre-treatment investigations [16].
Direct comparison of the findings of our study with other stud-
ies of salvage brachytherapy is challenging due to variations in the
numbers of patients included, risk categories of primary disease,
differences in pre-treatment diagnostic imaging and biopsy tech-
Table 3
Outcomes following focal salvage HDR brachytherapy.
Outcome Number (%)
Median (range) nadir PSA 0.27 (0.01–2.8)
Further disease relapse
None 25 (58%)
Biochemical progression 9 (21%)
Local recurrence 6 (14%)
Local and nodal recurrence 1 (2%)
Distant metastatic disease 1 (2%)
Median (range) PSA at time of relapse 2.7 (1.83–16.5)
Further treatments received
None 12 (67% of 18 patients with relapse)
ADT/maximum androgen blockade 4 (22%)
Enzalutamide/abiraterone 2 (11%)
Chemotherapy 1 (6%)
Radionuclide therapy 1 (6%)
Table 4
Planning objectives and achieved dosimetric parameters for focal salvage brachyther-
apy delivered in a single fraction of 19 Gy.
Planning
objective
Median value
(range)
% of plans that
adhered to
objectives
Focal PTV Volume 19.4 cm3
(8.5–43.0 cm3)
Focal-PTV D90% (Gy) >17.1 Gy 18.6 Gy
(15.1–20.4 Gy)
95%
Focal PTV V19Gy (%) >90% 88.5%
(64.0–95.9%)
35%*
Urethra D10% (Gy)
(Hard constraint**)
<20.9 Gy 16.96 Gy
(6.3–20.8 Gy)
100%
Rectum D2cm3 (Gy) <12.35 Gy 8.3 Gy
(3.1–12.1 Gy)
100%
* Note clinical protocol limited coverage to hard constraint of the urethra.
** Soft constraint for Urethra D10% was <14.25 Gy for patients treated before 23/02/
2015 (50% of patients met soft constraint) and <17.1 Gy for patients treated after
23/02/2015 (61% of patients met soft constraint).
Table 5
Toxicity following focal salvage HDR brachytherapy.
Toxicity Grade 1 Grade 2 Grade 3
Acute genitourinary 12 (28%) 27 (63%) 0
Acute gastrointestinal 6 (14%) 0 0
Late genitourinary 10 (23%) 18 (42%) 1 (2%)
Late gastrointestinal 6 (14%) 0 0
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fractionation schedules of HDR, use of whole gland versus focal
gland treatments, use of different imaging-based planning tech-
niques, use and duration of ADT and varying durations of follow
up. Nevertheless, our median bPFS of 35 months is comparable
to the prospective study of focal salvage HDR brachytherapy by
Murgic et al. where median bPFS was 33 months [10]. In addition,
our 2 and 3 year estimates for bPFS of 70.6% and 41.8% are compa-
rable to the findings of the study by Chitmanee et al. where 2 and
3 year bPFS was 63% and 46% respectively [8]. Our 3 year estimate
for bPFS of 41.8% is lower than the study by Murgic et al. (61%),
although that study only evaluated 15 patients and our cohort
included a greater proportion of patients with high risk character-
istics which could potentially explain the lower result seen in our
study [10]. Other studies of focal salvage HDR brachytherapy either
included only small numbers or had limited follow up [9,15]. Few
studies of focal salvage LDR brachytherapy exist but this could be a
promising technique with 3 year estimates for bPFS reported
between 60 and 71% [13,14].In comparison, studies of whole gland salvage HDR or LDR
brachytherapy have reported 3 and 5 year estimates of bPFS rang-
ing from 46 to 88% and 20–87% respectively [17–37]. However, tox-
icity with whole gland salvage brachytherapy remains a concern.
While our study is retrospective and did not include patient
reported outcome measures (PROMs) and therefore is at risk of
underrepresenting actual levels of toxicity, we only had one patient
(2%) with a grade  3 GU toxicity. Our toxicity rates are similar to
previous studies of focal salvage HDR and LDR brachytherapy [8–
10,13–15]. As a comparison, the rates of grade  3 GU and GI toxi-
cities reported in previous studies of whole gland salvage
brachytherapy are as high as 47% and 20% respectively [17–38].
There is no clear consensus about the role of ADT with focal sal-
vage HDR brachytherapy. In our study, where the use of and dura-
tion of ADT was at clinician discretion, 74% of patients received
ADT and this was for 6 months in most cases. ADT was used in
many previous studies of whole gland salvage brachytherapy but
it was not used in several studies of focal salvage HDR and LDR
brachytherapy [7,10,13,14,39,40]. The rationale for this approach
could be that salvage brachytherapy might avoid/delay the need
to commence ADT and its associated toxicities and impact on qual-
ity of life [10].
There are few high quality studies directly comparing different
imaging techniques in the recurrent PCa setting meaning that the
optimal restaging imaging to select patients for salvage
brachytherapy remains uncertain [11]. However, the majority of
recent studies have focussed on the use of mp-MRI and PET-CT
for local and distant staging. The poor sensitivity of computed
tomography (CT) and isotope bone scintigraphy for the detection
of metastatic PCa at PSA levels < 10 ng/ml has been previously
demonstrated [41]. Since these imaging techniques were used to
select patients in many of the previous studies of salvage
brachytherapy, it has been suggested that this could be one reason
for subsequent biochemical failure [10]. The majority of patients in
our study were restaged after primary treatment failure using mp-
MRI (81%) and PET-CT (79%). There is increasing evidence of high
detection rates using mp-MRI for the evaluation of local recur-
rence, including after primary radiotherapy [11,12]. Regarding
metastatic disease, the best detection rates, especially at low PSA
values and for small volume disease, may be seen with 68 Ga PSMA
PET-CT [11,42]. It might be that the optimum strategy for restaging
prior to salvage brachytherapy is a combination of mp-MRI and
68 Ga PSMA PET-CT to evaluate local recurrence and exclude regio-
nal/distant metastases respectively [11].
In our study, the majority of patients underwent transperineal
biopsies from four quadrants (± targeted biopsies) of the prostate
with only 7% evaluated by transperineal prostate mapping (TPM).
This meant that a precise description of the site of relapse provided
by TPM was not possible in the majority of patients. The optimal
method for histological confirmation of locally recurrent PCa
remains unclear but there is increasing evidence to support the
use of MRI-targeted biopsies and MRI/ultrasound fusion-targeted
biopsies in the primary diagnostic setting [43–46]. These tech-
niques appear to detect more clinically significant cancers using
fewer biopsy cores compared with standard biopsy techniques. In
the recurrent PCa setting, a recent study compared MRI-targeted
biopsies with TPM and reported similar detection rates for higher
grade lesions but that TPM found a greater proportion of lower
grade disease [12].
There remain uncertainties regarding which patients are most
likely to benefit from salvage brachytherapy. In the treatment of
PCa, local control appears to be associated with a reduction in sub-
sequent development of distant metastatic disease and PCSM,
which provides a rationale for treating isolated local recurrences
with salvage therapies [47,48]. However, there is a risk that
patients with higher risk disease may be less likely to benefit from
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likely to have occult micrometastatic disease that is simply not
identified due to the limitations of current staging investigations
[4,49,50]. Stratifying patients based on PSA kinetics may help pre-
dict the likely response to salvage brachytherapy. The PSA nadir
post salvage was identified as a predictor of bPFS in previous stud-
ies [8,22,24,32]. This is consistent with the results of our study,
where nadir PSA < 0.2 ng/ml was associated with improved bPFS
post salvage. However, a potential alternative explanation for this
finding is that the majority of patients in our study received ADT in
combination with focal salvage brachytherapy. Previous authors
also reported that baseline PSA < 10 predicted for bPFS, although
we were unable to replicate this finding in our study [20,23,25].
Time to relapse post primary treatment may also indicate the likely
response to salvage brachytherapy since it was previously reported
that a relapse free period > 30 months was associated with better
bPFS [21,23,24]. We saw a trend regarding the same finding in our
study, although the result was not statistically significant. In a
recent meta-analysis of studies reporting outcomes after primary
RT, patients with interval to biochemical failure < 18 months or
Gleason score  8 (ISUP grade 4/5) had a higher risk of death from
any cause and PCSM [51]. The authors recommended that these
criteria could be used to classify patients with biochemical failure
into low and high risk categories. This information could aid deci-
sion making regarding the potential benefits and toxicities from
salvage therapy.
It is uncertain what the optimum dose/fractionation schedule is
for focal salvage HDR brachytherapy. In the primary disease set-
ting, there is concern that HDR monotherapy using 19 Gy in a sin-
gle fraction provides insufficient disease control in comparison to
fractionated regimens such as 27 Gy in 2 fractions [8,52–54].
Despite its convenience, there has to be concern that single fraction
treatments could also be inadequate in the setting of local recur-
rence. Therefore, future trials should evaluate fractionated rather
than single fraction focal salvage HDR brachytherapy.
Strengths of this study include its relatively large numbers of
patients in comparison to the majority of previous studies, espe-
cially studies of focal salvage brachytherapy. There was also con-
sistency in terms of dose and fractionation for all patients in the
series. Limitations of this study include its retrospective design
and modest duration of follow up. Not all of our patients were
restaged after primary treatment failure with both mp-MRI and
PET-CT meaning that we could have underestimated the extent
of local recurrence and distant disease. We have reported esti-
mates of bPFS at 3 years whereas some other studies of whole
gland salvage brachytherapy have described outcomes at 5 years
or longer. This reflects the relatively recent development of focal
salvage brachytherapy. We have evaluated association of various
factors with bPFS using univariable analyses but given the rela-
tively small numbers of patients in our study we did not perform
a multivariable analysis. We also cannot be certain about our rates
of local control and distant metastases for patients with biochem-
ical failure post salvage and therefore are unable to report clinical
progression free survival as an endpoint. This is because we per-
formed serial measurements of PSA to evaluate response to salvage
treatment rather than reassessment imaging/biopsies and at the
time of biochemical failure restaging investigations were not con-
sistently performed. Finally, although we describe clinician-
assessment toxicities, we did not include PROMs and therefore
could have underestimated actual levels of GU and GI toxicity.5. Conclusions
In our retrospective study, focal salvage HDR brachytherapy
appeared to achieve reasonable bPFS with low levels of severeGU and GI toxicity. Further evaluation within a clinical trial is
required to establish its role in the treatment of locally recurrent
PCa.6. Sources of support
No specific funding was received for this study. This work was
undertaken in Leeds Teaching Hospitals NHS Trust which receives
funding from NHS England. The views expressed in this publication
are those of the authors and not necessarily those of NHS England.
F Slevin reports grants from Cancer Research UK Centres Network
Accelerator Award Grant (A21993) to the Advanced Radiotherapy
Technologies Network (ART-NET) consortium during the conduct
of this study. AM Henry reports grants from Cancer Research UK
(108036) during the conduct of this study; grants from NIHR
(111218), grants from MRC (107154) and grants from Sir John
Fisher Foundation (charity, no grant number) outside the submit-
ted work.Declaration of Competing Interest
None.References
[1] Agarwal PK, Sadetsky N, Konety BR, et al. Treatment failure after primary and
salvage therapy for prostate cancer. Cancer 2008;112(2):307–14.
[2] Lazarev S, Thompson MR, Stone NN, et al. Low-dose-rate brachytherapy for
prostate cancer: outcomes at >10 years of follow-up. BJU Int 2018;121
(5):781–90.
[3] Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term
outcome for stages T1–T2 prostate cancer treated with permanent seed
implantation. Int J Rad Oncol Biol Phys 2007;67(2):327–33.
[4] Zumsteg ZS, Spratt DE, Romesser PB, et al. The natural history and predictors of
outcome following biochemical relapse in the dose escalation era for prostate
cancer patients undergoing definitive external beam radiotherapy. Eur Urol
2015;67(6):1009–16.
[5] Tran H, Kwok J, Pickles T, et al. Underutilization of local salvage therapy after
radiation therapy for prostate cancer11Funding: UBC Summer Student
Research Program. Urol Oncol 2014;32(5):701–6.
[6] European Association of Urology. Prostate cancer. 2019. Available from:
<https://uroweb.org/guideline/prostate-cancer/#note_484> [Accessed: 25/06/
2019].
[7] Steele EM, Holmes JA. A review of salvage treatment options for disease
progression after radiation therapy for localized prostate cancer. Urol Oncol
2019;37(9):582–98.
[8] Chitmanee PY, Tsang Hm Tharmalingam, et al. Single-dose focal salvage high
dose rate brachytherapy for locally recurrent prostate cancer. Clin Oncol.
[9] Maenhout M, Peters M, van Vulpen M, et al. Focal MRI-guided salvage high-
dose-rate brachytherapy in patients with radiorecurrent. Prostate Cancer
2017;16(6):1194–201.
[10] Murgic J, Morton G, Loblaw A, et al. Focal salvage high dose-rate brachytherapy
for locally recurrent prostate cancer after primary radiation therapy failure:
results from a prospective clinical trial. Int J Rad Oncol Biol Phys 2018;102
(3):561–7.
[11] De Visschere PJL, Standaert C, Fütterer JJ, et al. A systematic review on the role
of imaging in early recurrent prostate cancer. Eur Urol Oncol 2019;2(1):47–76.
[12] Kanthabalan A, Abd-Alazeez M, Arya M, et al. Transperineal magnetic
resonance imaging-targeted biopsy versus transperineal template prostate
mapping biopsy in the detection of localised radio-recurrent prostate cancer.
Clin Oncol (R Coll Radiol). 2016;28(9):568–76.
[13] Hsu CC, Hsu H, Pickett B, et al. Feasibility of MR imaging/MR spectroscopy-
planned focal partial salvage permanent prostate implant (PPI) for localized
recurrence after initial PPI for prostate cancer. Int J Rad Oncol Biol Phys
2013;85(2):370–7.
[14] Peters M, Maenhout M, van der Voort JRN, van Zyp, et al. Focal salvage iodine-
125 brachytherapy for prostate cancer recurrences after primary radiotherapy:
a retrospective study regarding toxicity, biochemical outcome and quality of
life. Radiother Oncol 2014;112(1):77–82.
[15] Zamboglou C, Rischke H-C, Meyer PT, et al. Single fraction multimodal image
guided focal salvage high-dose-rate brachytherapy for recurrent prostate
cancer. Cancer 2016;8(3):241–8.
[16] Kaljouw E, Pieters BR, Kovács G, et al. A Delphi consensus study on salvage
brachytherapy for prostate cancer relapse after radiotherapy, a Uro-GEC study.
Radiother Oncol 2016;118(1):122–30.
[17] Aaronson DS, Yamasaki I, Gottschalk A, et al. Salvage permanent perineal
radioactive-seed implantation for treating recurrence of localized prostate
26 F. Slevin et al. / Clinical and Translational Radiation Oncology 23 (2020) 20–26adenocarcinoma after external beam radiotherapy. BJU Int 2009;104
(5):600–4.
[18] Baumann BC, Baumann JC, Christodouleas JP, et al. Salvage of locally recurrent
prostate cancer after external beam radiation using reduced-dose
brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
Brachytherapy 2017;16(2):291–8.
[19] Beyer DC. Permanent brachytherapy as salvage treatment for recurrent
prostate cancer. Urology 1999;54(5):880–3.
[20] Burri RJ, Stone NN, Unger P, et al. Long-term outcome and toxicity of salvage
brachytherapy for local failure after initial radiotherapy for prostate cancer. Int
J Rad Oncol Biol Phys 2010;77(5):1338–44.
[21] Chen CP, Weinberg V, Shinohara K, et al. Salvage HDR brachytherapy for
recurrent prostate cancer after previous definitive radiation therapy: 5-year
outcomes. Int J Rad Oncol Biol Phys 2013;86(2):324–9.
[22] Grado GL, Collins JM, Kriegshauser JS, et al. Salvage brachytherapy for localized
prostate cancer after radiotherapy failure11Dr. Grado, Ms. Balch, and Ms.
Grado are currently in private radiation oncology/prostate brachytherapy
practice in Scottsdale, Arizona; Dr. Grado is also currently affiliated with Carle
Clinic, Urbana, Illinois. Urology 1999;53(1):2–10.
[23] Henríquez I, Sancho G, Hervás A, et al. Salvage brachytherapy in prostate local
recurrence after radiation therapy: predicting factors for control and toxicity.
Rad Oncol 2014;9(1):102.
[24] Henríquez López I, González-San Segundo C, Vegas JO, et al. Salvage
brachytherapy for locally-recurrent prostate cancer after radiation therapy: a
comparison of efficacy and toxicity outcomes with high-dose rate and low-
dose rate brachytherapy. Radiother Oncol 2019.
[25] Kollmeier MA, McBride S, Taggar A, et al. Salvage brachytherapy for recurrent
prostate cancer after definitive radiation therapy: a comparison of low-dose-
rate and high-dose-rate brachytherapy and the importance of prostate-specific
antigen doubling time. Brachytherapy 2017;16(6):1091–8.
[26] Koutrouvelis P, Hendricks F, Lailas N, et al. Salvage reimplantation in patient
with local recurrent prostate carcinoma after brachytherapy with three
dimensional computed tomography-guided permanent pararectal implant.
Technol Cancer Res Treat 2003;2(4):339–44.
[27] Loening SA, Turner JW. Use of percutaneous transperineal 198Au seeds to treat
recurrent prostate adenocarcinoma after failure of definitive radiotherapy.
Prostate 1993;23(4):283–90.
[28] Moman MR, van der Poel HG, Battermann JJ, et al. Treatment outcome and
toxicity after salvage 125-I implantation for prostate cancer recurrences after
primary 125-I implantation and external beam radiotherapy. Brachytherapy
2010;9(2):119–25.
[29] Nguyen PL, Chen MH, D’Amico AV, et al. Magnetic resonance image-guided
salvage brachytherapy after radiation in select men who initially presented
with favorable-risk prostate cancer: a prospective phase 2 study. Cancer
2007;110(7):1485–92.
[30] Peters M, van der Voort van Zyp JR, Moerland MA, et al. Multivariable model
development and internal validation for prostate cancer specific survival and
overall survival after whole-gland salvage Iodine-125 prostate brachytherapy.
Radiother Oncol 2016;119(1):104–10.
[31] Peters M, van der Voort JRN, van Zyp MA, Moerland, et al. Development and
internal validation of a multivariable prediction model for biochemical failure
after whole-gland salvage iodine-125 prostate brachytherapy for recurrent
prostate cancer. Brachytherapy 2016;15(3):296–305.
[32] Shimbo M, Inoue K, Koike Y, et al. Salvage <sup>125</sup>I seed implantation
for prostate cancer with postradiation local recurrence. Urol Int 2013;90
(3):294–300.
[33] Vargas C, Swartz D, Vashi A, et al. Salvage brachytherapy for recurrent prostate
cancer. Brachytherapy 2014;13(1):53–8.
[34] Wallner KE, Nori D, Morse MJ, et al. 125-iodine reimplantation for locally
progressive prostatic carcinoma. J Urol 1990;144:704–6.
[35] Wojcieszek P, Szlag M, Głowacki G, et al. Salvage high-dose-rate
brachytherapy for locally recurrent prostate cancer after primary
radiotherapy failure. Radiother Oncol 2016;119(3):405–10.[36] Wong WW, Buskirk SJ, Schild SE, et al. Combined prostate brachytherapy and
short-term androgen deprivation therapy as salvage therapy for locally
recurrent prostate cancer after external beam irradiation. J Urol 2006;176
(5):2020–4.
[37] Yamada Y, Kollmeier MA, Pei X, et al. A Phase II study of salvage high-dose-rate
brachytherapy for the treatment of locally recurrent prostate cancer after
definitive external beam radiotherapy. Brachytherapy 2014;13(2):111–6.
[38] Crook JM, Zhang P, Pisansky TM, et al. A prospective phase 2 trial of
transperineal ultrasound-guided brachytherapy for locally recurrent prostate
cancer after external beam radiation therapy (NRG/RTOG0526): initial report
of late toxicity outcome. Int J Rad Oncol Biol Phys 2017;99(2 Suppl):S1.
[39] Ben-Josef E, Lawrence TS. Using a bigger hammer: the role of stereotactic body
radiotherapy in the management of oligometastases. J Clin Oncol 2009;27
(10):1537–9.
[40] Maenhout M, Peters M, van Vulpen M, et al. Focal MRI-guided salvage high-
dose-rate brachytherapy in patients with radiorecurrent prostate cancer.
Technol Cancer Res Treat 2017;16(6):1194–201.
[41] Hovels AM, Heesakkers RA, Adang EM, et al. The diagnostic accuracy of CT and
MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a
meta-analysis. Clin Radiol 2008;63(4):387–95.
[42] Perera M, Papa N, Roberts M, et al. Gallium-68 prostate-specific membrane
antigen positron emission tomography in advanced prostate cancer-updated
diagnostic utility, sensitivity, specificity, and distribution of prostate-specific
membrane antigen-avid lesions: a systematic review and meta-analysis. Eur
Urol 2019.
[43] Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard
biopsy for prostate-cancer diagnosis. N Engl J Med 2018;378(19):1767–77.
[44] Kasivisvanathan V, Stabile A, Neves JB, et al. Magnetic resonance imaging-
targeted biopsy versus systematic biopsy in the detection of prostate cancer: a
systematic review and meta-analysis. Eur Urol 2019;76(3):284–303.
[45] Moore CM, Robertson NL, Arsanious N, et al. Image-guided prostate biopsy
using magnetic resonance imaging-derived targets: a systematic review. Eur
Urol 2013;63(1):125–40.
[46] Valerio M, Donaldson I, Emberton M, et al. Detection of clinically significant
prostate cancer using magnetic resonance imaging-ultrasound fusion targeted
biopsy: a systematic review. Eur Urol 2015;68(1):8–19.
[47] Fuks Z, Leibel SA, Wallner KE, et al. The effect of local control on metastatic
dissemination in carcinoma of the prostate: long-term results in patients
treated with 1251 implantation. Int J Rad Oncol Biol Phys 1991;21(3):537–47.
[48] Zelefsky MJ, Reuter VE, Fuks Z, et al. Influence of local tumor control on distant
metastases and cancer related mortality after external beam radiotherapy for
prostate cancer. J Urol 2008;179(4):1368–73.
[49] Morgan PB, Hanlon AL, Horwitz EM, et al. Timing of biochemical failure and
distant metastatic disease for low-, intermediate-, and high-risk prostate
cancer after radiotherapy. Cancer 2007;110(1):68–80.
[50] Zhou P, Chen M-H, McLeod D, et al. Predictors of prostate cancer-specific
mortality after radical prostatectomy or radiation. Therapy 2005;23
(28):6992–8.
[51] Van den Broeck T, van den Bergh RCN, Arfi N, et al. Prognostic value of
biochemical recurrence following treatment with curative intent for prostate
cancer: a systematic review. Eur Urol 2019;75(6):967–87.
[52] Mendez LC, Ravi A, Chung H, et al. Pattern of relapse and dose received by the
recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer
treated with single fraction 19 Gy high-dose-rate brachytherapy.
Brachytherapy 2018;17(2):291–7.
[53] Prada PJ, Cardenal J, Blanco AG, et al. High-dose-rate interstitial brachytherapy
as monotherapy in one fraction for the treatment of favorable stage prostate
cancer: toxicity and long-term biochemical results. Radiother Oncol 2016;119
(3):411–6.
[54] Siddiqui ZA, Gustafson GS, Ye H, et al. Five-year outcomes of a single-
institution prospective trial of 19-Gy single-fraction high-dose-rate
brachytherapy for low- and intermediate-risk prostate cancer. Int J Rad
Oncol Biol Phys 2019;104(5):1038–44.
